Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 14/20 | 1.00 |
| ▸ | EGFR | P00533 | 3/20 | 0.58 |
| ▸ | TXK | P42681 | 7/20 | 0.57 |
| ▸ | BTK | Q06187 | 6/20 | 0.57 |
| ▸ | TEC | P42680 | 4/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15575510 | 0.89 | ITK (1.00) | ITKEGFRTXKBTKTEC | |
| SCHEMBL15575533 | 0.86 | ITK (0.81) | ITKEGFRTXKBTKTEC | |
| SCHEMBL18532275 | 0.84 | ITK (0.73) | ITKTXKBTKTECOPRM1 | |
| SCHEMBL15574314 | 0.83 | ITK (0.72) | ITKEGFROPRM1OPRD1OPRK1 | |
| SCHEMBL15574178 | 0.83 | ITK (0.72) | ITKTXKBTKTECOPRM1 | |
| SCHEMBL21303375 | 0.82 | ITK (0.75) | ITKEGFRTXKBTKTEC | |
| SCHEMBL16896022 | 0.81 | EGFR (0.83) | ITKEGFRBTKCYP3A4CYP2C9 | |
| SCHEMBL16895993 | 0.81 | EGFR (0.83) | ITKEGFRBTKCYP3A4CYP2C9 | |
| SCHEMBL15574299 | 0.81 | ITK (0.79) | ITKTXKBTKTEC | |
| SCHEMBL15574297 | 0.81 | ITK (0.79) | ITKTXKBTKTEC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2890691-B1 | BENZIMIDAZOLE DERIVATIVES AS ITK INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2018-04-25 | — | — | EP | disclosed |
| EP-2890691-B1 | BENZIMIDAZOLE DERIVATIVES AS ITK INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2018-04-25 | — | — | EP | disclosed |
| US-9573958-B2 | Benzimidazole derivatives as ITK inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573958-B2 | Benzimidazole derivatives as ITK inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573958-B2 | Benzimidazole derivatives as ITK inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20150225412-A1 | BENZIMIDAZOLE DERIVATIVES AS ITK INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2015-08-13 | — | — | US | disclosed |
| US-20150225412-A1 | BENZIMIDAZOLE DERIVATIVES AS ITK INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2015-08-13 | — | — | US | disclosed |
| US-20150225412-A1 | BENZIMIDAZOLE DERIVATIVES AS ITK INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2015-08-13 | — | — | US | disclosed |
| EP-2890691-A1 | BENZIMIDAZOLE DERIVATIVES AS ITK INHIBITORS | Principia Biopharma Inc. (US) | 2015-07-08 | — | — | EP | disclosed |
| WO-2014036016-A1 | BENZIMIDAZOLE DERIVATIVES AS ITK INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-03-06 | — | — | WO | disclosed |
| WO-2014036016-A1 | BENZIMIDAZOLE DERIVATIVES AS ITK INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225412-A1 | BENZIMIDAZOLE DERIVATIVES AS ITK INHIBITORS | BMX, ITK, BLK | ITK 2/4885EGFR 62/4885TXK 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.